Snake and venom

 Snakes are a group of reptiles belonging to the suborder Serpentes. They are known for their elongated, legless bodies and specialized adaptations for hunting and defense. Some snakes produce venom, a toxic substance that they use to immobilize or kill prey, as well as for defense against predators. Not all snakes are venomous; in fact, most species are non-venomous.

Venomous snakes use their venom in various ways:

1. Prey Immobilization: Venom contains a mixture of proteins that can cause paralysis, disrupt blood clotting, or break down tissues, allowing the snake to subdue and digest its prey more easily.

2. Defense: Venom also serves as a defense mechanism, deterring potential predators from attacking the snake.

There are several types of venomous snakes, including:

• Cobra family (Elapidae): Includes species like the king cobra and coral snake. These snakes have neurotoxic venom, which affects the nervous system and can cause paralysis or death.

• Viper family (Viperidae): Includes species like rattlesnakes, vipers, and pit vipers. Their venom often contains hemotoxins, which can destroy tissue and blood cells, causing severe internal bleeding.

• Colubrids: Some species in this large snake family, such as the boomslang, are mildly venomous, though they are less dangerous to humans compared to the larger venomous species.

Venom is typically delivered through specialized fangs or grooves in the snake's mouth, and the composition of venom can vary widely between species, affecting how dangerous or useful it is in different ecological contexts. 

Enzalutamide target in cancer cell

 Enzalutamide primarily targets the androgen receptor (AR) in prostate cancer cells.

Key Target: Androgen Receptor (AR)

The androgen receptor (AR) is a nuclear hormone receptor found on prostate cancer cells. It plays a critical role in regulating cell growth, survival, and metastasis by binding to androgens (like testosterone and dihydrotestosterone). When androgens bind to the AR, the receptor becomes activated and promotes the transcription of genes that drive cancer cell division and survival.

How Enzalutamide Targets the AR:

1. Androgen Receptor Antagonism: Enzalutamide binds to the androgen receptor and prevents androgens (like testosterone) from binding to the receptor. This stops the receptor from becoming activated.

2. Prevents AR Nuclear Translocation: Normally, when the AR is activated, it moves to the nucleus of the cell, where it triggers gene expression that promotes cancer growth. Enzalutamide blocks this nuclear translocation, preventing the AR from initiating these growth signals.

3. Inhibits AR DNA Binding: Even if the androgen receptor enters the nucleus, enzalutamide prevents the AR from binding to DNA and activating the expression of genes involved in cancer cell proliferation.

4. Promotes AR Degradation: Enzalutamide may also promote the degradation of the androgen receptor itself, decreasing its levels in cancer cells.

In Summary:

Enzalutamide targets the androgen receptor (AR) by:

• Blocking androgen binding
• Preventing AR nuclear translocation
• Inhibiting AR DNA binding
• Promoting AR degradation

This mechanism is particularly effective in treating castration-resistant prostate cancer (CRPC), where prostate cancer cells continue to grow even when testosterone levels are reduced, and the androgen receptor remains a key driver of cancer progression.

To express the mechanism of Enzalutamide targeting the androgen receptor (AR) in a more mathematical or formulaic way, we can break it down into components and actions that can be represented symbolically:

Mathematical Representation of Enzalutamide's Mechanism:

Let’s define:

• AR = Androgen Receptor (a protein found in prostate cancer cells).
• T = Testosterone (or other androgens).
• Enza = Enzalutamide (the drug).
• AR-T = Active androgen-receptor complex (when testosterone binds to AR).
• AR-Enza = Inactive androgen-receptor complex (when enzalutamide binds to AR).
• DNA = DNA inside the cell, where AR typically binds to initiate gene expression.
• Gene = Genes that promote cell growth and survival, activated by AR binding to DNA.

1. Androgen Receptor Antagonism (Binding Prevention):

$\text{AR} + T \rightarrow \text{AR-T} \quad \text{(Activation of AR)}$ Enzalutamide binds to the AR, blocking testosterone from binding: $\text{AR} + \text{Enza} \rightarrow \text{AR-Enza} \quad \text{(Inactive AR complex)}$ $\text{AR-Enza} + T \rightarrow \text{No Activation of AR} \quad \text{(Enza prevents AR activation)}$

2. Prevents AR Nuclear Translocation (Prevents AR movement to the nucleus):

Normally, AR-T moves into the nucleus to activate genes: $\text{AR-T} \rightarrow \text{AR (nucleus)}$ Enzalutamide prevents this nuclear translocation: $\text{AR-Enza} \quad \text{(No translocation to nucleus)}$

3. Inhibits AR DNA Binding (Prevents gene activation):

In the nucleus, AR-T binds to DNA to activate genes: $\text{AR-T (nucleus)} + \text{DNA} \rightarrow \text{Gene Activation (cell growth)}$ Enzalutamide inhibits this binding: $\text{AR-Enza (nucleus)} + \text{DNA} \rightarrow \text{No Gene Activation}$

4. Promotes AR Degradation (Reduces AR levels):

Enzalutamide may induce the breakdown of the androgen receptor: $\text{AR-Enza} \rightarrow \text{Degraded AR}$

Summary Formulaic Representation:

1. AR + T → AR-T (Testosterone binding to AR activates it)
2. AR + Enza → AR-Enza (Enzalutamide binds and blocks activation)
3. AR-Enza + T → No AR Activation (Enza prevents AR activation by testosterone)
4. AR-Enza → No Nuclear Translocation (Prevents AR from entering the nucleus)
5. AR-Enza + DNA → No Gene Activation (Inhibits AR binding to DNA)
6. AR-Enza → Degraded AR (Promotes AR degradation)

Impact on Cancer Cells:

Since AR is a key driver of prostate cancer cell growth, by preventing AR activation, translocation, and DNA binding, Enzalutamide slows or halts the cancer cells' growth and survival, making it effective in treating castration-resistant prostate cancer (CRPC).

Best drug for the treatment of breast cancer.

The treatment of breast cancer depends on various factors, including the type and stage of cancer, as well as the individual patient's health. There isn't a single "best" drug for all cases of breast cancer, but several highly effective drugs are commonly used based on the cancer's characteristics, such as hormone receptor status, HER2 status, and whether the cancer is early or metastatic.

Here are some of the best and most commonly used drugs for treating breast cancer:

1. Hormone Receptor-Positive (HR+) Breast Cancer

• Tamoxifen:
• Mechanism: Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors on breast cancer cells, which prevents estrogen from stimulating the growth of the tumor.
• Used For: Early-stage and metastatic estrogen receptor-positive (ER+) breast cancer.
• Side Effects: Hot flashes, increased risk of blood clots, endometrial cancer, and mood changes.
• Aromatase Inhibitors (e.g., Anastrozole, Letrozole, Exemestane):
• Mechanism: These drugs lower estrogen levels by inhibiting the enzyme aromatase, which converts androgens to estrogen. They are primarily used in postmenopausal women.
• Used For: Postmenopausal patients with hormone receptor-positive breast cancer.
• Side Effects: Joint pain, osteoporosis, hot flashes, and fatigue.
• Fulvestrant:
• Mechanism: A type of hormone therapy that works by blocking estrogen receptors and promoting the degradation of these receptors.
• Used For: Metastatic hormone receptor-positive breast cancer, especially in patients who have developed resistance to other hormone therapies.
• Side Effects: Hot flashes, nausea, and injection site reactions.

2. HER2-Positive Breast Cancer

HER2 (Human Epidermal Growth Factor Receptor 2) is a protein that promotes the growth of cancer cells. About 20-25% of breast cancers are HER2-positive.

• Trastuzumab (Herceptin):
• Mechanism: Trastuzumab is a monoclonal antibody that targets the HER2 receptor, inhibiting the growth of HER2-positive breast cancer cells and triggering immune responses to destroy them.
• Used For: Early-stage, metastatic HER2-positive breast cancer.
• Side Effects: Heart problems (such as cardiomyopathy), fever, chills, and fatigue.
• Pertuzumab (Perjeta):
• Mechanism: Pertuzumab is another monoclonal antibody that targets HER2, but it works differently than trastuzumab by binding to a different part of the HER2 receptor, making it an effective combination therapy.
• Used For: HER2-positive breast cancer, often in combination with trastuzumab and chemotherapy.
• Side Effects: Diarrhea, fatigue, nausea, and heart issues.
• Ado-Trastuzumab Emtansine (Kadcyla):
• Mechanism: This drug is a combination of trastuzumab linked to a chemotherapy drug (DM1). It delivers the chemotherapy directly to HER2-positive cancer cells.
• Used For: Metastatic HER2-positive breast cancer, especially after other treatments have failed.
• Side Effects: Low blood counts, liver toxicity, heart problems, and nausea.

3. Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer does not express estrogen receptors, progesterone receptors, or HER2, making it harder to treat with hormone therapies or HER2-targeted treatments. It is often more aggressive.

• Chemotherapy: Common chemotherapy agents used for TNBC include:
• Paclitaxel
• Docetaxel
• Carboplatin
• Doxorubicin
• Immunotherapy: Newer options include immunotherapies like Atezolizumab (Tecentriq) and Pembrolizumab (Keytruda), which target PD-L1 and help the immune system recognize and attack cancer cells.
• Side Effects: Chemotherapy side effects include nausea, hair loss, low blood counts, and fatigue. Immunotherapy side effects include fatigue, skin rashes, and possible autoimmune reactions.

4. CDK4/6 Inhibitors (for HR-positive, HER2-negative breast cancer)

• Palbociclib (Ibrance), Ribociclib (Kisqali), Abemaciclib (Verzenio):
• Mechanism: These drugs inhibit cyclin-dependent kinases (CDK4/6), which are involved in cell division. By blocking these kinases, these drugs can slow or stop the growth of HR-positive, HER2-negative breast cancers.
• Used For: HR-positive, HER2-negative, metastatic breast cancer, often in combination with hormone therapy.
• Side Effects: Low blood counts, infections, fatigue, and liver issues.

5. PARP Inhibitors

• Olaparib (Lynparza) and Talazoparib (Talzenna):
• Mechanism: These drugs target cancer cells with defective DNA repair mechanisms (like those with BRCA mutations). By inhibiting the repair of DNA damage, PARP inhibitors help kill cancer cells.
• Used For: Metastatic breast cancer in patients with BRCA1 or BRCA2 mutations (often in triple-negative breast cancer).
• Side Effects: Nausea, fatigue, anemia, and risk of infections.

6. Other Drugs

• Capecitabine (Xeloda):
• Mechanism: A chemotherapy drug that is taken orally and is converted into 5-fluorouracil (5-FU) in the body to target cancer cells.
• Used For: Metastatic breast cancer, often after other treatments have failed.
• Side Effects: Hand-foot syndrome (redness, swelling, and pain in the palms and soles), diarrhea, and nausea.
• Everolimus (Afinitor):
• Mechanism: This drug inhibits the mTOR pathway, which is involved in cell growth and survival.
• Used For: HR-positive, HER2-negative, metastatic breast cancer, often in combination with aromatase inhibitors.
• Side Effects: Mouth sores, rash, diarrhea, and risk of infection.

Conclusion:

The best drug for breast cancer treatment largely depends on the specific subtype of breast cancer and the individual patient's health. Hormone therapies (like tamoxifen or aromatase inhibitors) are commonly used for hormone receptor-positive breast cancer, while HER2-targeted therapies (like trastuzumab and pertuzumab) are highly effective for HER2-positive cancers. For more aggressive or treatment-resistant cases, chemotherapy, immunotherapy, or targeted therapies such as CDK4/6 inhibitors and PARP inhibitors might be considered.

Treatment is personalized, and oncologists often use a combination of drugs and therapies for the most effective results. Always consult with a healthcare provider for the most appropriate treatment options based on the specific type and stage of breast cancer.

• Summary of Top Drugs and Their Effectiveness:

Drug	Type of Cancer	Effectiveness	Side Effects
Tamoxifen	ER-positive breast cancer	Reduces recurrence by 40-50%	Hot flashes, blood clots, endometrial cancer risk
Letrozole / Anastrozole	ER-positive, postmenopausal	Reduces recurrence by 30-50%	Joint pain, osteoporosis, hot flashes
Trastuzumab (Herceptin)	HER2-positive breast cancer	Reduces recurrence by 50% with chemotherapy	Heart issues, fever, chills
Pertuzumab (Perjeta)	HER2-positive breast cancer	Adds 10-15% improvement in survival with chemo	Diarrhea, fatigue, heart issues
Chemotherapy (e.g., Paclitaxel)	Triple-negative breast cancer	Reduces recurrence by 30-50% in early-stage TNBC	Hair loss, nausea, fatigue
Palbociclib (Ibrance)	HR-positive, HER2-negative metastatic cancer	Improves progression-free survival by 6-12 months	Low blood counts, fatigue, liver problems
Olaparib (Lynparza)	Metastatic BRCA-positive breast cancer	Improves progression-free survival by 4-6 months	Nausea, fatigue, anemia, infection risk

 

Karyotyping for Chromosomal Aberrations by Giemsa Stain protocol

 

List of top scientist working on cancer biology

 

The field of cancer research is vast and interdisciplinary, with scientists across the world contributing to understanding cancer's biology, developing new treatments, and improving prevention strategies. Here are some of the top scientists currently working on cancer research, along with their areas of focus and notable contributions.

 

 1. James P. Allison

   - Institution: MD Anderson Cancer Center, University of Texas

   - Area of Research: Immunotherapy, Cancer Immunology

   - Notable Contribution: James P. Allison is best known for his pioneering work in cancer immunotherapy, particularly his development of immune checkpoint inhibitors like Ipilimumab (Yervoy) for treating melanoma. His work focuses on harnessing the body's immune system to fight cancer.

   - Awards: Nobel Prize in Physiology or Medicine (2018, shared with Tasuku Honjo) for discoveries in cancer immunotherapy.

 

 2. Tasuku Honjo

   - Institution: Kyoto University, Japan

   - Area of Research: Immunotherapy, Cancer Immunology

   - Notable Contribution: Tasuku Honjo discovered PD-1, an immune checkpoint protein, and developed therapies that block it, leading to the approval of PD-1 inhibitors like Nivolumab (Opdivo) and Pembrolizumab (Keytruda). These drugs have revolutionized cancer treatment.

   - Awards: Nobel Prize in Physiology or Medicine (2018, shared with James P. Allison).

 

 3. Mary-Claire King

   - Institution: University of Washington, USA

   - Area of Research: Cancer Genetics, Breast Cancer

   - Notable Contribution: Mary-Claire King discovered the BRCA1 gene, which is linked to a significantly increased risk of breast and ovarian cancer. Her work has led to advances in genetic testing and preventive care for women at risk.

   - Awards: National Medal of Science (2009).

 

 4. David Baltimore

   - Institution: California Institute of Technology (Caltech)

   - Area of Research: Cancer Biology, Virology

   - Notable Contribution: David Baltimore is a pioneer in the study of cancer-causing viruses and the role of retroviruses in cancer development. His research helped identify key regulatory pathways for gene expression that are critical for cancer cell survival.

   - Awards: Nobel Prize in Physiology or Medicine (1975) for his discovery of the enzyme reverse transcriptase.

 

 5. Huda Y. Zoghbi

   - Institution: Baylor College of Medicine, Texas Children's Hospital

   - Area of Research: Genetics, Epigenetics, Cancer and Neurological Diseases

   - Notable Contribution: Zoghbi's work has expanded our understanding of epigenetic regulation and how gene mutations contribute to neurodegenerative diseases and certain cancers. She also focuses on the genetic underpinnings of glioblastoma.

   - Awards: Shaw Prize in Life Science (2011).

 

 6. Frederick W. Alt

   - Institution: Boston Children's Hospital, Harvard Medical School

   - Area of Research: Cancer Immunology, DNA Repair

   - Notable Contribution: Alt is a leader in understanding the role of DNA recombination and repair in the development of cancer. His research has illuminated how genetic mutations affect cancer development and led to advances in treatments for immune diseases and cancers.

   - Awards: Canada Gairdner International Award (2019).

 

 7. Brian Druker

   - Institution: Oregon Health & Science University (OHSU)

   - Area of Research: Targeted Therapies, Leukemia

   - Notable Contribution: Druker’s research was instrumental in the development of Imatinib (Gleevec), a targeted therapy for chronic myelogenous leukemia (CML). His work has helped set the standard for developing drugs that specifically target cancer-causing mutations.

   - Awards: Lasker Award for Clinical Medical Research (2009).

 

 8. Ronald DePinho

   - Institution: University of Texas MD Anderson Cancer Center

   - Area of Research: Tumorigenesis, Cancer Metabolism

   - Notable Contribution: DePinho’s work focuses on the molecular pathways involved in tumorigenesis, with a particular emphasis on the role of telomeres and telomerase in cancer. He has made important contributions to understanding the role of aging in cancer biology.

   - Awards: Numerous NIH grants and honors for his contributions to cancer biology.

 

 9. Robert Weinberg

   - Institution: MIT, Whitehead Institute for Biomedical Research

   - Area of Research: Tumor Suppressors, Oncogenes

   - Notable Contribution: Robert Weinberg is a leader in cancer biology and is best known for his discovery of the first cancer-causing gene (oncogene), Ras, and for his work on the p53 tumor suppressor gene. His research has provided fundamental insights into cancer genetics.

   - Awards: Breakthrough Prize in Life Sciences (2013).

 

 10. Sandy H. L. Schlesinger

   - Institution: Weill Cornell Medical College, USA

   - Area of Research: Cancer Cell Biology, Translational Research

   - Notable Contribution: Schlesinger’s work focuses on drug resistance in cancer therapy, studying how cancer cells evade treatment. She has been instrumental in developing new therapies to overcome resistance to common cancer drugs.

   - Awards: Numerous honors for her contributions to cancer therapy.

 

 11. Elizabeth Blackburn

   - Institution: University of California, San Francisco (UCSF)

   - Area of Research: Telomeres, Aging, Cancer

   - Notable Contribution: Elizabeth Blackburn’s discovery of telomerase (an enzyme that maintains telomeres) has revolutionized our understanding of the aging process and its relationship to cancer. Her research has implications for both aging-related diseases and cancer.

   - Awards: Nobel Prize in Physiology or Medicine (2009).

 

 12. Charles Sawyers

   - Institution: Memorial Sloan Kettering Cancer Center, New York

   - Area of Research: Targeted Cancer Therapies, Drug Resistance

   - Notable Contribution: Sawyers is a leader in the development of targeted therapies for cancers with specific genetic mutations. He was instrumental in the development of drugs like Imatinib for CML and Dasatinib for treating other cancers.

   - Awards: Numerous honors for contributions to cancer therapeutics.

 

 13. Mary Beth Callahan

   - Institution: Dana-Farber Cancer Institute, Harvard Medical School

   - Area of Research: Pediatric Cancer, Cancer Stem Cells

   - Notable Contribution: Callahan's work focuses on the role of cancer stem cells in pediatric cancers, including leukemia and brain tumors. She is studying innovative therapies to target these cells.

   - Awards: Various recognitions for her work in pediatric cancer research.

 

 14. David Page

   - Institution: MIT

   - Area of Research: Genomics, Sex Chromosome Biology

   - Notable Contribution: David Page's work has provided new insights into how X and Y chromosomes contribute to cancer and how genomic diversity affects cancer risk and progression.

   - Awards: Numerous awards for his work in genomics and cancer biology.

 

 15. Jennifer Doudna

   - Institution: University of California, Berkeley

   - Area of Research: CRISPR-Cas9 Gene Editing

   - Notable Contribution: Doudna co-discovered CRISPR-Cas9, a revolutionary gene-editing technology that has profound potential for treating genetic disorders and cancer. Her work may enable precise gene therapies for various cancers.

   - Awards: Nobel Prize in Chemistry (2020, shared with Emmanuelle Charpentier).

 

---

 

 Conclusion 

The scientists listed above are at the forefront of cancer research, making significant strides in understanding the genetic, biological, and immune mechanisms of cancer. Their work spans several critical areas, including immunotherapy, targeted treatments, genetic discoveries, cancer biology, and clinical trials. If you're looking for more detailed research or specific publications from these researchers, many of their studies are published in high-impact journals such as *Nature*, *Science*, *The New England Journal of Medicine*, and *Cell*.

 

Let me know if you'd like to explore the work of any of these scientists in more detail!

Protocol for cancer cell viability analysis by using the MTT assay

The MTT assay will be performed to determine the cell viability of cancer cells.  

1. Seed approximately 10,000 cells/well will be seeded in 96-well plates.

2. Keep in the incubator at 37 ◦C under an atmosphere containing 5% CO2.  

3. After overnight incubation to allow them to adhere, the cells will be fed with fresh medium containing varying concentrations of the respective compound and further incubated in different h. 

4. Briefly, at the stipulated time following the treatment of the test compound, the medium will be aspirated and MTT (5 mg/mL) will be added in each well of the 96-well culture plate, and incubation will continue at 37 ◦C  for 2-3 h. 

5. The plates will be spun, supernatants will be discarded, and purple-colored formazan precipitates will be dissolved in 100 μL of dimethylsulfoxide (DMSO). 

6. The color absorbance will be recorded at 590 nm on a microplate reader (BioTek Instruments, Inc. USA). 

7. IC50 concentration (concentration at which the biological response is reduced by 50%)  values will be determined for the cell viability inhibitory potential of the  test compounds.    

Role of fish and fish products in cancer treatments.

 

 Although it's crucial to emphasise that fish isn't a cancer cure in and of itself, fish and fish-based products can help prevent and treat cancer in a number of ways. Nonetheless, certain characteristics of fish can be advantageous when incorporated into a nutritious diet, either as part of a cancer prevention plan or during treatment.

Fish can aid in the treatment of cancer in the following ways:

 1. EPA and DHA, or omega-3 fatty acids
Omega-3 fatty acids are abundant in fish, particularly fatty fish like herring, sardines, mackerel, and salmon. These have been investigated because they may:

2. Decrease inflammation: Omega-3 fatty acids can aid in lowering inflammation, which is a major contributor to the onset and spread of numerous malignancies. 

3. Immunity: The body may be able to combat cancer cells more effectively if omega-3 fatty acids are able to boost immune cell activity.

4. Enhance the efficiency of cancer therapies: According to some research, omega-3 fatty acids may lessen treatment-related side effects such muscular atrophy and cachexia, as well as increase the effectiveness of some cancer treatments like chemotherapy. Research indicates that the proliferation of cancer cells may be inhibited by omega-3 fatty acids. This is especially true for cancers such as breast, prostate, and colon cancer.

 5. Excellent Protein
When receiving cancer treatment, especially if a patient is receiving chemotherapy or radiation therapy, fish is an excellent, easily digestible source of protein. Nausea, exhaustion, and appetite loss are common side effects of cancer therapies, making it challenging to keep a balanced diet high-quality fish protein can be beneficial.

6. Preserve muscle mass: Fish is a great choice for people who might have trouble consuming other foods high in protein, and protein is crucial for preserving muscle mass and strength throughout therapy.

7. Support healing and recovery: Protein is essential for wound healing, immune system maintenance, and general recuperation.

8. Vitamin D:
Vitamin D is found in fatty fish, such as mackerel, salmon, and tuna. According to research, having enough vitamin D may help prevent cancer, especially colon, prostate, and breast cancer. Immune system function, bone health (particularly during cancer treatments that may weaken bones), and general health all depend on vitamin D.

 9. Bioactive Substances

Other bioactive substances like selenium and astaxanthin, an antioxidant present in salmon and other fish, are also present in some fish species, particularly fatty fish. Although additional research is required to completely grasp their involvement, many chemicals have been examined for their potential anticancer properties. Low in Saturated Fats Fish, especially those that are lean, are often Compared to red meats, fish—especially lean fish—generally have fewer saturated fats. A lower risk of some cancers, especially colorectal and colon cancer, has been linked to a diet lower in saturated fats.

 Things to Think About

Although eating fish can help with cancer therapy, it's vital to keep the following in mind:

Contaminants and Mercury: High quantities of mercury in some large fish, such as swordfish, tuna, and shark, can be dangerous, particularly for those with compromised immune systems.

Mercury and Contaminants: High mercury concentrations, which can be hazardous, particularly for those with compromised immune systems, can be found in some large fish, such as swordfish, tuna, and shark. Fish with reduced mercury levels, such as trout, sardines, and salmon, should be prioritized.

 

Dietary restrictions or allergies: Some people may choose plant-based diets or have fish allergies. Plant-based omega-3 sources, such as flaxseeds, chia seeds, or algal supplements, may be substitutes in these situations.

The following are cancer-specific diets: Dietary guidelines can change based on the type of cancer and the treatment being administered. For instance, changes in food texture may be necessary to address swallowing difficulties in cases of head and neck cancer, or easy-to-digest meals may be given preference in situations of gastrointestinal cancer.

 Final Thoughts

Because it provides vital nutrients including protein, vitamin D, and omega-3 fatty acids—all of which can help the body during treatment—fish can be a significant component of a cancer patient's balanced diet. However, cancer treatment regimens should always be customised to meet the needs of each patient, therefore seeking individualised guidance from a healthcare professional or dietitian is crucial.

It's a good idea to talk to your oncologist or a qualified dietitian about your nutrition if you're receiving cancer treatment or are thinking about making dietary adjustments. They can advise you on the foods that will best support your treatment objectives and overall health.